Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Articles tagged with "COVID-19"

How to Maintain Connections with Colleagues, Staff & Patients During a Pandemic: A Q&A with Reshma Khan, MD

Linda Childers  |  April 17, 2020

As the cases of COVID-19 continue to rise in South Florida, Reshma Khan, MD, a rheumatologist at the Palm Beach Rheumatology and Wellness Center, Jupiter, Fla., is being careful to emphasize social distancing, but not social isolation. Dr. Khan believes that, during this pandemic, it’s more important than ever for rheumatologists to share support and…

Patients Need Psychosocial Support Now More Than Ever: Q&A with Adena Batterman, MSW, LCSW

Susan Bernstein  |  April 17, 2020

How are rheumatology professionals affected by the physical distancing and other challenges presented by COVID-19? The Rheumatologist interviewed Adena Batterman, MSW, LCSW, senior manager of inflammatory arthritis support and education programs at the Hospital for Special Surgery, New York, to discuss how the pandemic has changed the way she and her staff maintain continuity of…

The COVID-19 Crisis: Uncharted Waters & the ACR’s Response

Ellen M. Gravallese, MD  |  April 15, 2020

Singer Jimmy Dean reportedly once said, “I can’t change the direction of the wind, but I can adjust my sails to always reach my destination.” The COVID-19 pandemic has required us as rheumatologists to adjust our sails multiple times. We have had to rethink many of the ways in which we interact with our worried…

New Processes May Stick Around After the Pandemic: Q&A with Wendy Ramey, BSPharm, RPh, CSP

Susan Bernstein  |  April 13, 2020

How are COVID-19 and physical distancing restrictions at work affecting rheumatology professionals? The Rheumatologist interviewed clinical pharmacist Wendy Ramey, BSPharm, RPh, CSP, to discuss how the pandemic has changed the way her staff supports rheumatologists at the University of Kentucky Specialty Pharmacy and Infusion Services, Lexington. Ms. Ramey describes how these unprecedented times affect patients,…

2 Patients on Different DMARDs Experience Different COVID-19 Disease Courses

Luis A. Marcos, MD, MPH, Saika Sharmeen, DO, Jaime Gonzalez, MD, Qingping Yao, MD, PhD, Bettina Fries, MD, & Jack Fuhrer, MD  |  April 13, 2020

In March 2020, an elderly married couple living on Long Island, N.Y., presented to our emergency department with symptoms suspicious for COVID-19 infection. The wife, a-76-year-old woman, presented with complaints of subjective fevers, minimal dry cough and headaches of one-week duration. She denied having any chills, rhinorrhea, diarrhea, abdominal pain or shortness of breath. Two…

Data on Arthritis Drug to Treat Coronavirus Could Come within Weeks

Michael Erman & Axel Threlfall  |  April 10, 2020

(Reuters)—Initial data from clinical trials testing whether patients with severe coronavirus illness can be helped by a rheumatoid arthritis drug sold by Regeneron Pharmaceuticals Inc and Sanofi SA may come as early as next week, Regeneron’s chief scientific officer told Reuters. “We could be one to two weeks—at most a month or so—away from knowing…

Amneal Running Out of HCQ Raw Material Due to Finnish Restrictions

Michael Erman & Anne Kauranen  |  April 10, 2020

NEW YORK/HELSINKI (Reuters)—Amneal Pharmaceuticals could soon run out of the raw ingredients to make more of the anti-malarial drug hydroxychloroquine (HCQ) that has been touted as a potential treatment for COVID-19 because Finland is keeping the drug for domestic use, according to the generic drugmaker’s chief executives. Amneal has committed to producing about 20 million…

A Collaborative Website as a Communication Model During the COVID-19 Pandemic

Sheryl Mascarenhas, MD, with Greg Stevens, BS  |  April 10, 2020

Under the onslaught of developing information on COVID-19, one health system found a way to streamline communication using a secure tool it already had access to.

A Transition to 90% Telemedicine: Q&A with Karim Masri, MD

Susan Bernstein  |  April 9, 2020

How are COVID-19 and current restrictions on physical distancing affecting rheumatologists? The Rheumatologist interviewed Karim Masri, MD, to ask how the pandemic has changed the way he and his clinic staff deliver patient care, and how these unprecedented times affect patients, staff and life outside the office. Dr. Masri is a practicing rheumatologist at Bon…

FDA Accelerates Approvals of Generic Versions of HCQ

U.S. Food and Drug Administration  |  April 8, 2020

On April 7, the FDA approved an Abbreviated New Drug Application (ANDA) for Hydroxychloroquine Sulfate Tablets USP, 200 mg, for the treatment of: 1) uncomplicated malaria due to P. falciparum, P. malariae, P. ovale and P. vivax; 2) chronic discoid lupus erythematosus and systemic lupus erythematosus in adults; and 3) treatment of acute and chronic…

  • « Previous Page
  • 1
  • …
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences